COVID-19 and diabetes mellitus: from pathophysiology to clinical management.
Reads0
Chats0
TLDR
Evidence suggests that insulin and dipeptidyl peptidase 4 inhibitors can be used safely in patients with diabetes mellitus and COVID-19; metformin and sodium–glucose cotransporter 2 inhibitors might need to be withdrawn in patients at high risk of severe disease.Abstract:
Initial studies found increased severity of coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in patients with diabetes mellitus. Furthermore, COVID-19 might also predispose infected individuals to hyperglycaemia. Interacting with other risk factors, hyperglycaemia might modulate immune and inflammatory responses, thus predisposing patients to severe COVID-19 and possible lethal outcomes. Angiotensin-converting enzyme 2 (ACE2), which is part of the renin-angiotensin-aldosterone system (RAAS), is the main entry receptor for SARS-CoV-2; although dipeptidyl peptidase 4 (DPP4) might also act as a binding target. Preliminary data, however, do not suggest a notable effect of glucose-lowering DPP4 inhibitors on SARS-CoV-2 susceptibility. Owing to their pharmacological characteristics, sodium-glucose cotransporter 2 (SGLT2) inhibitors might cause adverse effects in patients with COVID-19 and so cannot be recommended. Currently, insulin should be the main approach to the control of acute glycaemia. Most available evidence does not distinguish between the major types of diabetes mellitus and is related to type 2 diabetes mellitus owing to its high prevalence. However, some limited evidence is now available on type 1 diabetes mellitus and COVID-19. Most of these conclusions are preliminary, and further investigation of the optimal management in patients with diabetes mellitus is warranted.read more
Citations
More filters
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Fei Zhou,Ting Yu,Ronghui Du,Guohui Fan,Ying Liu,Zhibo Liu,Jie Xiang,Yeming Wang,Bin Song,Xiaoying Gu,Xiaoying Gu,Lulu Guan,Yuan Wei,Li Hui,Xudong Wu,Jiuyang Xu,Shengjin Tu,Yi Zhang,Hua Chen,Bin Cao +19 more
TL;DR: Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future.
Journal ArticleDOI
Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda,Kate Maclagan,Simon S. Skene,Martha Bajwa-Joseph,Dawn Letchford,Kashfia Chowdhury,Steve Hibbert,Natalia Budnik,Luca Zampedri,John Dickson,Yazhou Li,Iciar Aviles-Olmos,Thomas T. Warner,Patricia Limousin,Andrew J. Lees,Nigel H. Greig,Susan Tebbs,Thomas Foltynie +17 more
TL;DR: Exenatide had positive effects on practically defined off-medication motor scores in Parkinson's disease, which were sustained beyond the period of exposure, and effects on everyday symptoms should be examined in longer-term trials.
Journal ArticleDOI
Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning.
TL;DR: The increased prevalence of obesity, diabetes, and cardiovascular risk factors in people hospitalized with severe COVID-19 illness has engendered considerable interest in the metabolic aspects of SARS-CoV-2-induced pathophysiology as mentioned in this paper.
Journal ArticleDOI
Clinical Characteristics of COVID-19
TL;DR: Though COVID-19 mainly affects the respiratory system, disease may cause widespread systemic and organ specific symptoms involving gastrointestinal, neurological, cardiovascular, immunological, cutaneous, hematological and coagulation systems.
Journal ArticleDOI
ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries.
Shivaprakash M Rudramurthy,Martin Hoenigl,Martin Hoenigl,Jacques F. Meis,Oliver A. Cornely,Valliappan Muthu,Jean-Pierre Gangneux,John R. Perfect,Arunaloke Chakrabarti,Ecmm,Isham +10 more
TL;DR: In this article, the authors provided a comprehensive document to help clinicians in managing COVID-19-associated mucormycosis (CAM) globally, driven particularly by low and middle-income countries.
References
More filters
Journal ArticleDOI
Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers.
TL;DR: The Btk inhibitor ibrutinib can upregulate VEGF expression, inhibit the expression of TLRs, inhibitThe secretion of inflammatory factors, promote ulcer healing, and promote the healing of diabetic foot ulcer possibly by regulating the RAGE/NF-κB pathway.
Journal ArticleDOI
Diabetic ketoacidosis in an HIV patient: a new mechanism of HIV protease inhibitor-induced glucose intolerance.
Virginia L. Kan,Eric S. Nylen +1 more
Journal ArticleDOI
In vitro inhibition of human UGT isoforms by ritonavir and cobicistat.
TL;DR: Ritonavir and cobicistat are unlikely to produce clinically important drug interactions involving drugs metabolized to glucuronide conjugates by UGT1A1,1A3, 1A6, 1B9, 2B4 and 2B7.
Journal ArticleDOI
COVID-19, Type 1 Diabetes Clinical Practice, Research, and Remote Medical Care: A View From the Land Down-Under.
Journal ArticleDOI
Dipeptidyl peptidase-4 inhibitors have adverse effects for the proliferation of human T cells.
Noriyuki Kitagawa,Masahide Hamaguchi,Saori Majima,Takuya Fukuda,Toshihiro Kimura,Yoshitaka Hashimoto,Muhei Tanaka,Masahiro Yamazaki,Naoto Nakamura,Michiaki Fukui +9 more
TL;DR: Taken together, DPP4i modulated TCR signaling, which contributed to attenuate the proliferation of CD4 and CD8, which has adverse effects for theiferation of human T cells.
Related Papers (5)
Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes.
Lihua Zhu,Zhi-Gang She,Xu Cheng,Juan Juan Qin,Xiao Jing Zhang,Jingjing Cai,Fang Lei,Haitao Wang,Jing Xie,Wenxin Wang,Haomiao Li,Peng Zhang,Xiaohui Song,Xi Chen,Xiang Mei,Chaozheng Zhang,Liangjie Bai,Da Xiang,Ming Ming Chen,Yanqiong Liu,Youqin Yan,Mingyu Liu,Weiming Mao,Jinjing Zou,Liming Liu,Guohua Chen,Pengcheng Luo,Bing Xiao,Changjiang Zhang,Zixiong Zhang,Zhigang Lu,Junhai Wang,Haofeng Lu,Xigang Xia,Daihong Wang,Xiaofeng Liao,Gang Peng,Ping Ye,Jun Yang,Yufeng Yuan,Xiaodong Huang,Jiao Guo,Bing Hong Zhang,Hongliang Li +43 more
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
Zunyou Wu,Jennifer M. McGoogan +1 more
Clinical Characteristics of Coronavirus Disease 2019 in China.
Wei-jie Guan,Zhengyi Ni,Yu Hu,Wenhua Liang,Chun-Quan Ou,Jianxing He,Lei Liu,Hong Shan,Chunliang Lei,David S.C. Hui,Bin Du,Lanjuan Li,Guang Zeng,Kowk-Yung Yuen,Ruchong Chen,Chun-Li Tang,Tao Wang,Ping-Yan Chen,Jie Xiang,Shiyue Li,Jinlin Wang,Zi-jing Liang,Yi-xiang Peng,Li Wei,Yong Liu,Ya-hua Hu,Peng Peng,Jian-ming Wang,Ji-yang Liu,Zhong Chen,Gang Li,Zhi-jian Zheng,Shao-qin Qiu,Jie Luo,Chang-jiang Ye,Shao-yong Zhu,Nanshan Zhong +36 more